
Amicus Therapeutics ApS


c/o Regus, Rådhuspladsen 16, DK-1550 København
V

Annual Report for 23 February - 31 December 2018

CVR No 39 35 93 40

The Annual Report was
presented and adopted at
the Annual General
Meeting of the Company on
31/5 2019

Simon Collins
Chairman of the General
Meeting



Contents

	<u>Page</u>
Management's Statement and Auditor's Report	
Management's Statement	1
Practitioner's Statement on Compilation of Financial Statements	2
Company Information	
Company Information	3
Financial Statements	
Income Statement 23 February - 31 December	4
Balance Sheet 31 December	5
Notes to the Financial Statements	6

Management's Statement

The Executive Board and Board of Directors have today considered and adopted the Annual Report of Amicus Therapeutics ApS for the financial year 23 February - 31 December 2018.

The Annual Report is prepared in accordance with the Danish Financial Statements Act. The Company complies with the exemption provisions governing the omission to have its Financial Statements audited.

In our opinion the Financial Statements give a true and fair view of the financial position at 31 December 2018 of the Company and of the results of the Company operations for 2018.

We recommend that the Annual Report be adopted at the Annual General Meeting.

København, 31 May 2019

Executive Board

Johnny Krogh Hansen
Executive Officer

Board of Directors

Simon Collins
Chairman

Johnny Krogh Hansen

Lori Mochan

Practitioner's Statement on Compilation of Financial Statements

To the Management of Amicus Therapeutics ApS

We have compiled the Financial Statements of Amicus Therapeutics ApS for the financial year 23 February - 31 December 2018 on the basis of the Enterprise's accounting records and other information you have provided.

The Financial Statements comprise income statement, balance sheet and notes, including a summary of significant accounting policies.

We performed our work in accordance with ISRS 4410, Engagements to Compile Financial Information.

Based on our professional expertise, we have assisted you with the preparation and presentation of the Financial Statements in accordance with the Danish Financial Statements Act. We have complied with relevant provisions of the Danish Act on Approved Auditors and Audit Firms and FSR – Danish Auditors' Code of Ethics, including the principles of integrity, objectivity, professional competence and due care.

The Financial Statements and the accuracy and completeness of the information forming the basis of the compilation of the Financial Statements are your responsibility.

As an engagement to compile financial information is not an assurance engagement, we are under no duty to verify the accuracy or completeness of the information you provided to us to compile the Financial Statements. Accordingly, we express no audit opinion or review opinion as to whether the Financial Statements have been prepared in accordance with the Danish Financial Statements Act.

Hellerup, 31 May 2019

PricewaterhouseCoopers

Statsautoriseret Revisionspartnerselskab

CVR No 33 77 12 31

Allan Knudsen

statsautoriseret revisor

mne29465

Company Information

The Company

Amicus Therapeutics ApS
c/o Regus
Rådhuspladsen 16
DK-1550 København V

CVR No: 39 35 93 40
Financial period: 23 February - 31 December
Municipality of reg. office: København

Board of Directors

Simon Collins, Chairman
Johnny Krogh Hansen
Lori Mochan

Executive Board

Johnny Krogh Hansen

Auditors

PricewaterhouseCoopers
Statsautoriseret Revisionspartnerselskab
Strandvejen 44
DK-2900 Hellerup

Income Statement 23 February - 31 December

	<u>Note</u>	<u>2018</u> DKK
Gross profit/loss		1,979,408
Staff expenses	2	<u>-1,885,151</u>
Profit/loss before financial income and expenses		94,257
Profit/loss before tax		94,257
Tax on profit/loss for the year	3	<u>-20,724</u>
Net profit/loss for the year		73,533

Distribution of profit

Proposed distribution of profit

Retained earnings	<u>73,533</u>
	73,533

Balance Sheet 31 December

	Note	2018 DKK
Assets		
Receivables from group enterprises		1,979,408
Receivables		1,979,408
Currents assets		1,979,408
Assets		1,979,408
Liabilities and equity		
Share capital		50,000
Retained earnings		73,533
Equity	4	123,533
Payables to group enterprises		1,835,151
Corporation tax		20,724
Short-term debt		1,855,875
Debt		1,855,875
Liabilities and equity		1,979,408
Key activities	1	
Contingent assets, liabilities and other financial obligations	5	
Accounting Policies	6	

Notes to the Financial Statements

1 Key activities

The Company's key activities are marketing, distributing and selling products and services within the pharmaceutical industry.

2 Staff expenses

	2018 DKK
Wages and salaries	1,757,974
Pensions	90,877
Other social security expenses	36,300
	1,885,151

Average number of employees	2
------------------------------------	----------

3 Tax on profit/loss for the year

Current tax for the year	20,724
	20,724

4 Equity

	Share capital DKK	Retained earnings DKK	Total DKK
Equity at 23 February	50,000	0	50,000
Net profit/loss for the year	0	73,533	73,533
Equity at 31 December	50,000	73,533	123,533

5 Contingent assets, liabilities and other financial obligations

Contingent liabilities

The Company has no contingent liabilities on 31 December 2018.

Notes to the Financial Statements

6 Accounting Policies

The Annual Report of Amicus Therapeutics ApS for 2018 has been prepared in accordance with the provisions of the Danish Financial Statements Act applying to enterprises of reporting class B.

The Financial Statements for 2018 are presented in DKK.

Recognition and measurement

Revenues are recognised in the income statement as earned. Furthermore, value adjustments of financial assets and liabilities measured at fair value or amortised cost are recognised. Moreover, all expenses incurred to achieve the earnings for the year are recognised in the income statement, including depreciation, amortisation, impairment losses and provisions as well as reversals due to changed accounting estimates of amounts that have previously been recognised in the income statement.

Assets are recognised in the balance sheet when it is probable that future economic benefits attributable to the asset will flow to the Company, and the value of the asset can be measured reliably.

Liabilities are recognised in the balance sheet when it is probable that future economic benefits will flow out of the Company, and the value of the liability can be measured reliably.

Assets and liabilities are initially measured at cost. Subsequently, assets and liabilities are measured as described for each item below.

Income Statement

Revenue

Revenue from the sale of goods is recognised when the risks and rewards relating to the goods sold have been transferred to the purchaser, the revenue can be measured reliably and it is probable that the economic benefits relating to the sale will flow to the Company.

Services are recognised at the rate of completion of the service to which the contract relates by using the percentage-of-completion method, which means that revenue equals the selling price of the service completed for the year. This method is applied when total revenues and expenses in respect of the service and the stage of completion at the balance sheet date can be measured reliably, and it is probable that the economic benefits, including payments, will flow to the Company. The stage of completion is determined on the basis of the ratio between the expenses incurred and the total expected expenses of the service.

Revenue is measured at the consideration received and is recognised exclusive of VAT and net of discounts relating to sales.

Notes to the Financial Statements

6 Accounting Policies (continued)

Gross profit/loss

With reference to section 32 of the Danish Financial Statements Act, gross profit/loss is calculated as a summary of revenue.

Staff expenses

Staff expenses comprise wages and salaries as well as payroll expenses.

Tax on profit/loss for the year

Tax for the year consists of current tax for the year and changes in deferred tax for the year. The tax attributable to the profit for the year is recognised in the income statement, whereas the tax attributable to equity transactions is recognised directly in equity.

The Company is jointly taxed with wholly owned Danish and foreign subsidiaries. The tax effect of the joint taxation is allocated to enterprises in proportion to their taxable incomes.

Balance Sheet

Receivables

Receivables are measured in the balance sheet at the lower of amortised cost and net realisable value, which corresponds to nominal value less provisions for bad debts.

Current tax receivables and liabilities

Current tax liabilities and receivables are recognised in the balance sheet as the expected taxable income for the year adjusted for tax on taxable incomes for prior years and tax paid on account. Extra payments and repayment under the on-account taxation scheme are recognised in the income statement in financial income and expenses.

Debts

Debts are measured at amortised cost, substantially corresponding to nominal value.